Diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources or derived from the flavonoid hesperidin. Diosmin is considered to be a vascular-protecting agent used to treat chronic venous insufficiency, hemorrhoids, lymphedema, and varicose veins. As a flavonoid, diosmin also exhibits anti-inflammatory, free-radical scavenging, and antimutagenic properties.
Diosmin differs molecularly from hesperidin by the presence of a double bond between two carbon atoms in diosmin’s central carbon ring. Diosmin can be manufactured by extracting hesperidin from citrus rinds, followed by conversion of hesperidin to diosmin. Diosmin has been used for more than 30 years as a phlebotonic and vascular-protecting agent, and has recently begun to be investigated for other therapeutic purposes, including cancer, premenstrual syndrome, colitis, and diabetes.
Function of Diosmin
1.Diosmin has antioxidant, antiinflammatory, hypolipidemic, vasoprotective and anticarcinogenic and cholesterol lowering actions
2.Diosmin can inhibit following enzymes: Phospholipase A2, lipoxygenase, HMG-CoA reductase and cyclo-oxygenase.
3.Diosmin can improve the health of capillaries by reducing the capillary permeabilit
4.Diosmin can be used to reduce hay fever and other allergic conditions by inhibiting the release of histamine from mast cells.
5.Diosmin can excite the heart and shrink the blood vessel, and then causes the hypertension.
Application of Diosmin
1. Applied in food field, it is used as a flavor enhancer and sweetener in a wide variety of alcoholicbeverage, dessert foods and savory foods.
2. Applied in cosmetics, it can added into toothpaste and mouth wash.
3. Applied in pharmaceutical field, it is mainly used to reducing the bitterness of in form.
1.Desnoyers P. General pharmacological review of Daflon. In: European symposium on venous disease and its treatment. Rome, April 1978. Selected papers published by Gazette Medicale de France, 1987: 17–21.
2.Kissel P, Royer R. Contribution au traitement de la maladie veineuse, Etude par la plethysmographie gazeuse d’un nouveau prineipe vaso-actif. Therapeutique 1970;46:907–9.
3.Klemn J. Clinical and pharmacological study of the venous action of Daflon using the clearance of xenon 133. Gazette Medicale de France 1976;83:3158–65.
4.Annoni F, Boccasanta P, Chiurazzi D, Mozzi E, Oberhauser V. Treatment of acute symptoms of hemorrhoid disease with high-dose oral 0-(beta-hydroxy-ethyl) rutosides. Minerva Med 1986;77:1663–8.
5.Thorp RH, Hughes ES. A clinical trial of trihydroxy-ethyl-rutoside (“VAREMOID”) in the treatment of hemorrhoid. Med J Aust 1970;2:1076–8.
6.Clyne MB, Freeling P, Ginsborg S. Troxerutin in the treatment of hemorrhoids. Practitioner 1967;198:420–3.
7.Goligher JC. Surgery of the anus, rectum and colon. 5th ed. London: Bailliere Tindall, 1984:101.
8.Thomson WS. The nature of haemorrhoids. Br J Surg 1975;62:542–52.
9.Webster DJ, Gough DC, Craven JL. The use of bulk evacuant in patients with haemorrhoids. Br J Surg 1978;65:291–2.
10.Moesgaard F, Nielsen ML, Hansen JB, Knudsen JT. High-fiber diet reduces bleeding and pain in patients with hemorrhoids. Dis Colon Rectum 1982;25:454–6.